Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in HER2-negative Advanced Breast Cancer with FGFR Alterations
NCT05560334Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05560334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560334.